Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study

PURPOSE: The optimal treatment strategy for patients with metastatic non-clear cell type renal cell carcinoma (nccRCC) remains unclear. Although several inhibitors of vascular endothelial growth factor have recently shown efficacy against nccRCC, the clinical benefit of pazopanib in nccRCC has not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Ki Sun, Lee, Su Jin, Park, Se Hoon, Lee, Jae-Lyun, Lee, Se-Hoon, Lim, Jae Yun, Kang, Jung Hun, Lee, Suee, Rha, Sun Young, Lee, Kyung Hee, Kim, Ho Young, Lim, Ho Yeong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912146/
https://www.ncbi.nlm.nih.gov/pubmed/28546525
http://dx.doi.org/10.4143/crt.2016.584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912146/
https://www.ncbi.nlm.nih.gov/pubmed/28546525
http://dx.doi.org/10.4143/crt.2016.584

Ejemplares similares